Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration
Bristol Myers Squibb exercised its first option and entered into a global license agreement with Immatics for the most a…
Bristol Myers Squibb exercised its first option and entered into a global license agreement with Immatics for the most a…
. - Wichtige wissenschaftliche Erfolge Treiben die Erweiterung der Pipeline von MOLECULAR GLUE DEGRADERS voran - Leistun…
ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-cl…
. - VERLÄNGERUNG UND AUSWEITUNG DER ZUSAMMENARBEIT UM 8 JAHRE ZUR ENTWICKLUNG EINER PIPELINE VON „MOLECULAR GLUE DEGRAD…